A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.
The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.
Exact Sciences Stock Tumbles After Firm Lowers Full-Year Revenue Guidance, Misses Q3 Estimates
The company's CEO said that results and resulting downward adjustment of its full-year guidance don't reflect its true potential, citing plans to do better in 2025.
China Instrument Sales Drag on Revvity Life Science Segment as Company Q3 Revenues Rise 2 Percent
Premium
Similar to other firms, the firm said that it has been negatively impacted as customers in China wait for government stimulus funding to arrive.
Next Implementation Steps Unclear After EU Parliament Votes to Support IVD Regulation Review
Premium
The parliamentary resolution drew the immediate support of MedTech Europe and VDGH, but it remains unclear what the immediate outcome of the resolution will be.